PARADIGM-HF trial of Novartis' LCZ696 for chronic heart failure closes early based on strength of interim results - Seite 3
About Novartis
Novartis provides innovative healthcare solutions that address the evolving needs of patients and societies. Headquartered in Basel, Switzerland, Novartis offers a diversified portfolio to best
meet these needs: innovative medicines, eye care, cost-saving generic pharmaceuticals, preventive vaccines and diagnostic tools, over-the-counter and animal health products. Novartis is the only
global company with leading positions in these areas. In 2013, the Group achieved net sales of USD 57.9 billion, while R&D throughout the Group amounted to approximately USD 9.9 billion (USD
9.6 billion excluding impairment and amortization charges). Novartis Group companies employ approximately 136,000 full-time-equivalent associates and operate in more than 140 countries around the
world.
For more information, please visit http://www.novartis.com.
Novartis is on Twitter. Sign up to follow @Novartis at http://twitter.com/novartis.
# # #
Novartis Media Relations
Central media line : +41 61 324 2200 | |
Eric Althoff Novartis Global Media Relations +41 61 324 7999 (direct) +41 79 593 4202 (mobile) eric.althoff@novartis.com |
Dermot Doherty Novartis Global Media Relations +41 61 696 8653 (direct) +41 79 536 9755 (mobile) dermot.doherty@novartis.com |
e-mail: media.relations@novartis.com
For Novartis multimedia content, please visit www.thenewsmarket.com/Novartis
For questions about the site or required registration, please contact: journalisthelp@thenewsmarket.com.
Novartis Investor Relations
Central phone: | +41 61 324 7944 | ||
Samir Shah | +41 61 324 7944 | North America: | |
Pierre-Michel Bringer | +41 61 324 1065 | Stephen Rubino | +1 862 778 8301 |
Thomas Hungerbuehler | +41 61 324 8425 | Jill Pozarek | +1 212 830 2445 |
Isabella Zinck | +41 61 324 7188 | Susan Donofrio | +1 862 778 9257 |
e-mail: investor.relations@novartis.com | e-mail: investor.relations@novartis.com | ||
Lesen Sie auch
References:
[1] Clincaltrials.gov, NCT01035255 last accessed online 19 March 2014
[2] McMurray JJ, Packer M, Desai AS, et al. Dual angiotensin receptor and neprilysin inhibition as an alternative to angiotensin-converting enzyme inhibition in patients with chronic systolic heart
failure: rationale for and design of the Prospective comparison of ARNI with ACEI to Determine Impact on Global Mortality and morbidity in Heart Failure trial (PARADIGM-HF). Eur J Heart Fail
2013;15,1062-1073 (doi:10.1093/eurjhf/hft052)